Alzheimer's Research Moves Beyond Single-Drug Approach

After early amyloid-clearing drugs slowed cognitive decline by 29% but failed to stop it, researchers are pursuing combination strategies. Of 171 pipeline candidates, many now target tau buildup, brain inflammation, and nerve damage alongside amyloid—mirroring how HIV treatment shifted from single drugs to combinations. The pivot reflects recognition that Alzheimer's is too complex for one mechanism alone.